| Name | Title | Contact Details |
|---|
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass
At Molecular Assemblies, we are enabling the next era in biotechnology through a completely new approach to DNA synthesis utilizing natural processes. We are developing a platform-independent, scalable DNA synthesis technology designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably.
Chiesi USA, Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.